Progress of PD-1/PD-L1 inhibitors in the treatment of small-cell lung cancer
10.3760/cma.j.cn112152-20191218-00819
- VernacularTitle:程序性死亡受体1及程序性死亡受体配体1抑制剂在小细胞肺癌治疗中的进展
- Author:
Shuyang ZHANG
1
;
Yan WANG
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院内科 100021
- Keywords:
Carcinoma, small cell lung;
Immune checkpoint inhibitors;
Programmed cell death 1;
Programmed cell death-ligand 1
- From:
Chinese Journal of Oncology
2021;43(1):98-103
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer (SCLC) is a neuroendocrine tumor, which accounts for about 15% of all lung cancers. SCLC is characterized by rapid growth and tendency to widespread metastasis at the initial stage. Although high response rates to first-line chemotherapy are observed, most patients relapse less than few months. In the past 5 years, some clinical trials found that the immune checkpoint inhibitors (ICIs) were effective in SCLC, especially programmed cell death 1/ligand 1 (PD-1/L1). Given this situation, the treatment patterns of SCLC have changed. This article briefly reviews the researches and studies of ICIs in the treatment of SCLC to provide reference to the clinicians.
